Posted by Michael Wonder on 13 Feb 2023
Ironwood Pharmaceuticals announces FDA filing acceptance and priority review of supplemental new drug application for Linzess (linaclotide) for functional constipation in children and adolescents ages 6-17 years old
13 February 2023 - FDA assigns second quarter 2023 target action date.
Ironwood Pharmaceuticals today announced that the US FDA has granted priority review to the supplemental new drug application for Linzess (linaclotide) for the treatment of children and adolescents ages 6-17 years old with functional constipation.
